SBU’s Dr. Harold Paz appointed to a National Academies of Sciences, Engineering, and Medicine committee

Date:

[ad_1]

ALS, or Amyotrophic Lateral Sclerosis, is a rapidly progressive and invariably fatal neurological disease, for which there are currently no treatments to stop or reverse the illness.

But one Long Island healthcare leader aims to bring about change.

Stony Brook University’s Dr. Harold Paz was appointed to the  National Academies of  Sciences, Engineering, and Medicine ALS committee. Paz will serve on the Amyotrophic Lateral Sclerosis: Accelerating Treatments and Improving Quality of Life committee.

Paz is the executive vice president of Health Sciences at Stony Brook University and CEO at Stony Brook University Medicine. On the ALS committee, he will conduct a study to identify and recommend key actions for the public, private, and nonprofit sectors to undertake to make amyotrophic lateral sclerosis a livable disease within a decade.

“I’m delighted to have an opportunity to serve on this committee,” Paz said in a statement.

“It is an honor to be a part of a group working collaboratively to support ALS therapeutic development. Through this work, we hope to accelerate promising developments that will improve the quality of life of affected individuals and their families,” he added.

Stony Brook Medicine is the home of the Stony Brook Neuromuscular Disease and Christopher Pendergast ALS Center of Excellence, an ALS Association Certified Center providing comprehensive diagnosis and treatment for patients of all ages with neuromuscular disorders. This distinction recognizes Stony Brook’s collaborative approach and its ability to provide the highest quality care for people with ALS and their families.

The National Academies study, which is congressionally mandated and sponsored by the National Institutes of Health, will consider the landscape of ALS therapeutic development, care, services, and supports. Paz and the rest of the committee will develop a report with recommendations for key actions that federal agencies, the pharmaceutical industry, and nongovernmental organizations can take, including identifying opportunities for collaboration.

See also  Cantor: Feds weren’t paying attention in SVB failure

With over 25 years of leadership in health services and academic medicine, Paz has established himself as a nationally renowned healthcare leader with a unique combination of expertise in both academic medical centers and a Fortune 50 company. Paz is a recognized visionary who advocates a comprehensive model to address the health and wellness of individuals and communities in a rapidly evolving society. Throughout his career,  Paz’s research has focused on quality management, clinical outcomes, healthcare effectiveness and employee health benefit design. He has authored over 100 publications on these topics.



[ad_2]

Source link

Popular Posts

More like this
Related

The Power of Compound Interest: How Teens Can Grow Their Wealth

If you are a teenager, money is probably one...

Guide to luxury sport watches to indulge your competitive streak

Sport watchesaren’t always chunky with rubber straps. They’re not...

Damon salvatore rule number 34 Full Explained 2023 on TikTok

Rule 34 is an internet meme that states that...

How to Level Up Your Skills in Tunnel Rush Unblocked?

Tunnel Rush Unblocked sends you on a journey through...